Institute of Pathology, University of Cologne, Cologne, Germany.
Gastrointestinal Cancer Group Cologne GCGC, University of Cologne, Cologne, Germany.
Sci Rep. 2020 Oct 27;10(1):18411. doi: 10.1038/s41598-020-75085-7.
Valid biomarkers for a better prognostic prediction of the clinical course in esophageal adenocarcinoma (EAC) are still not implemented. Integrin alpha V (ITGAV), a transmembrane glycoprotein responsible for cell-to-matrix binding has been found to enhance tumor progression in several tumor entities. The expression pattern and biological role of ITGAV expression in esophageal adenocarcinoma (EAC) has not been analyzed so far. Aim of the study is to evaluate the expression level of ITGAV in a very large collective of EAC and its impact on individual patients´ prognosis. 585 patients with esophageal adenocarcinoma were analyzed immunohistochemically for ITGAV. The data was correlated with clinical, pathological and molecular data (TP53, HER2/neu, c-myc, GATA6, PIK3CA and KRAS). A total of 85 patients (14.3%) out of 585 analyzable tumors showed an ITGAV expression and intratumoral heterogeneity was low. ITGAV expression was correlated with a shortened overall-survival in the patients´ group that underwent primary surgery (p = 0.014) but not in the group of patients that received neoadjuvant treatment before surgery. No correlation between any of the analyzed molecular marker (mutations or amplifications) (TP53, HER2, c-myc, GATA6, PIK3CA and KRAS) and ITGAV expression could be observed. A multivariate cox-regression model was performed which showed tumor stage, lymph node metastasis and ITGAV expression as independent prognostic markers for overall-survival in the group of patients without neoadjuvant treatment. ITGAV expression is correlated with an impaired patient outcome in the group of patients without neoadjuvant therapy and serves as a prognostic factor in EAC.
尚未发现用于更好地预测食管腺癌 (EAC) 临床病程的有效生物标志物。整合素 αV (ITGAV) 是一种负责细胞与基质结合的跨膜糖蛋白，已被发现可增强几种肿瘤实体的肿瘤进展。ITGAV 在食管腺癌 (EAC) 中的表达模式和生物学作用尚未得到分析。本研究旨在评估 ITGAV 在非常大的 EAC 患者群体中的表达水平及其对个体患者预后的影响。对 585 例食管腺癌患者进行了 ITGAV 的免疫组织化学分析。将数据与临床、病理和分子数据（TP53、HER2/neu、c-myc、GATA6、PIK3CA 和 KRAS）相关联。在接受初次手术的患者组中，585 例可分析肿瘤中有 85 例（14.3%）表现出 ITGAV 表达，肿瘤内异质性较低（p = 0.014），但在接受术前新辅助治疗的患者组中没有相关性。未观察到任何分析的分子标志物（突变或扩增）（TP53、HER2、c-myc、GATA6、PIK3CA 和 KRAS）与 ITGAV 表达之间存在相关性。进行了多变量 cox 回归模型分析，结果显示，在未接受新辅助治疗的患者组中，肿瘤分期、淋巴结转移和 ITGAV 表达是总生存期的独立预后标志物。在未接受新辅助治疗的患者组中，ITGAV 表达与患者预后受损相关，是 EAC 的预后因素。
